Take­da punts dis­ap­point­ing late-stage Mil­len­ni­um drug for $7M in cash

Take­da has man­aged to of­fload an ex­per­i­men­tal can­cer drug that’s been sit­ting on the shelf — in ex­change for $7 mil­lion in cash plus mile­stones.

Puma Biotech­nol­o­gy is the buy­er for alis­ert­ib, an au­ro­ra ki­nase A in­hibitor, which it now plans to de­vel­op as a treat­ment of metasta­t­ic es­tro­gen re­cep­tor-pos­i­tive (ER-pos­i­tive) HER2-neg­a­tive breast can­cer, triple-neg­a­tive breast can­cer and small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER